Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PF-06671008 |
| Synonyms | |
| Therapy Description |
PF-06671008 is a protein that targets P-cadherin and potentially results in increased anti-tumor immune response (PMID: 29067496). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PF-06671008 | PF06671008|PF 06671008 | PF-06671008 is a protein that targets P-cadherin and potentially results in increased anti-tumor immune response (PMID: 29067496). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02659631 | Phase I | PF-06671008 | PF-06671008 Dose Escalation Study in Advanced Solid Tumors | Terminated | USA | 0 |